CAR4 T-cell therapy resulted in upregulation of all these markers in both tumor and immune cells and this was partly due to CAR4 T-cell-derived IFN-γ (Fig. 4b,c and Extended Data Fig. 5), possibly due to the additional contribution of type I IFNs. Here, IFNG is linked to neoplasm.